NovImmune, a Geneva, Switzerland-based drug discovery and development company with a focus on therapeutic monoclonal antibodies (mAbs) for inflammatory diseases and immune-related disorders, has raised CHF 20m in Series B financing.
The round was led by BZ Bank Aktiengesellschaft.
As stated by CEO Jack Barbut, this financing round will allow NovImmune to generate Proof-of-Concept data with at least two compounds, increase the number of partnerships, and complete the validation of its proprietary bispecific antibody generation platform (kappa-lambdabodies™).
The company has generated, to date, seven proprietary mAbs. The pipeline is a balance of preclinical and clinical compounds, with a mix of both clinically validated as well as novel targets. Three compounds are at this time in clinical development, with the most advanced in Phase II.
FinSMEs
17/12/2010